AbbVie files patent lawsuit over BeiGene’s cancer drug - Bloomberg
ijeab/iStock via Getty Images
- BeiGene (NASDAQ:BGNE) lost ~10% pre-market Thursday after Bloomberg Law reported that AbbVie (NYSE:ABBV) filed a lawsuit against the China-based company alleging a patent violation related to its blood cancer therapy Brukinsa.
- In the case filed in the U.S. District Court for the District of Delaware, AbbVie (ABBV) accused Brukinsa infringes a patent covering its blood cancer therapy Imbruvica, marketed by its Pharmacyclics unit and Johnson & Johnson's (NYSE:JNJ) Janssen Biotech.
- According to Bloomberg Law, AbbVie's (ABBV) Pharmacyclics unit filed the lawsuit the same day the patent for Imbruvica was issued.
- Brukinsa and Imbruvica are inhibitors of Bruton's tyrosine kinase (BTK). The oral medications are indicated in the U.S. for a range of hematological cancers such as Chronic lymphocytic leukemia (CLL), Mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia.